

MiCA White Paper

Bio Protocol

(BIO)

Version 1.1
Nov 2025

White Paper in accordance with Markets in Crypto Assets Regulation (MiCAR)
for the European Economic Area (EEA).

Purpose: seeking admission to trading EEA.

Prepared and Filed by LCX.com

NOTE: THIS CRYPTO-ASSET WHITE PAPER HAS NOT BEEN APPROVED BY ANY COMPETENT AUTHORITY IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA. THE PERSON SEEKING ADMISSION TO TRADING IS SOLELY RESPONSIBLE FOR THE CONTENT OF THIS CRYPTO-ASSET WHITE PAPER ACCORDING TO THE EUROPEAN ECONOMIC AREA'S MARKETS IN CRYPTO-ASSET REGULATION (MICA).

This white paper has been prepared in accordance with the requirements set forth in Commission Implementing Regulation (EU) 2024/2984, ensuring that all relevant reporting formats, content specifications, and machine-readable structures outlined in Annex I of this regulation have been fully mapped and implemented, particularly reflected through the Recitals, to enable proper notification under the Markets in Crypto-Assets Regulation (MiCAR).

Copyright:

This White Paper is under **copyright** of LCX AG Liechtenstein and may not be used, copied, or published by any third party without explicit written permission from LCX AG.

00 TABLE OF CONTENT

COMPLIANCE STATEMENTS	6
SUMMARY	7
A. PART A - INFORMATION ABOUT THE OFFEROR OR THE PERSON SEEKING ADMISSION TO TRADING	9
A.1 Name	9
A.2 Legal Form	9
A.3 Registered Address	9
A.4 Head Office	9
A.5 Registration Date	9
A.6 Legal Entity Identifier	9
A.7 Another Identifier Required Pursuant to Applicable National Law	9
A.8 Contact Telephone Number	9
A.9 E-mail Address	9
A.10 Response Time (Days)	9
A.11 Parent Company	9
A.12 Members of the Management Body	9
A.13 Business Activity	9
A.14 Parent Company Business Activity	10
A.15 Newly Established	10
A.16 Financial Condition for the past three Years	10
A.17 Financial Condition Since Registration	10
B. PART B - INFORMATION ABOUT THE ISSUER, IF DIFFERENT FROM THE OFFEROR OR PERSON SEEKING ADMISSION TO TRADING	11
B.1 Issuer different from offeror or person seeking admission to trading	11
B.2 Name	11
B.3 Legal Form	11
B.4 Registered Address	11
B.5 Head Office	11
B.6 Registration Date	11
B.7 Legal Entity Identifier	11
B.8 Another Identifier Required Pursuant to Applicable National Law	11
B.9 Parent Company	11
B.10 Members of the Management Body	11
B.11 Business Activity	11
B.12 Parent Company Business Activity	11
C. PART C - INFORMATION ABOUT THE OPERATOR OF THE TRADING PLATFORM IN CASES WHERE IT DRAWS UP THE CRYPTO-ASSET WHITE PAPER AND INFORMATION ABOUT OTHER PERSONS DRAWING THE CRYPTO-ASSET WHITE PAPER PURSUANT TO ARTICLE 6(1), SECOND SUBPARAGRAPH, OF REGULATION (EU) 2023/1114	12
C.1 Name	12
C.2 Legal Form	12
C.3 Registered Address	12
C.4 Head Office	12
C.5 Registration Date	12
C.6 Legal Entity Identifier	12
C.7 Another Identifier Required Pursuant to Applicable National Law	12

C.8 Parent Company	12
C.9 Reason for Crypto-Asset White Paper Preparation	12
C.10 Members of the Management Body	12
C.11 Operator Business Activity	12
C.12 Parent Company Business Activity	13
C.13 Other persons drawing up the white paper under Article 6 (1) second subparagraph MiCA	13
C.14 Reason for drawing up the white paper under Article 6 (1) second subparagraph MiCA	13
D. PART D - INFORMATION ABOUT THE CRYPTO-ASSET PROJECT	14
D.1 Crypto-Asset Project Name	14
D.2 Crypto-Assets Name	14
D.3 Abbreviation	14
D.4 Crypto-Asset Project Description	14
D.5 Details of all persons involved in the implementation of the crypto-asset project	14
D.6 Utility Token Classification	14
D.7 Key Features of Goods/Services for Utility Token Projects	14
D.8 Plans for the Token	15
D.9 Resource Allocation	15
D.10 Planned Use of Collected Funds or Crypto-Assets	15
E. PART E - INFORMATION ABOUT THE OFFER TO THE PUBLIC OF CRYPTO-ASSETS OR THEIR ADMISSION TO TRADING	16
E.1 Public Offering or Admission to Trading	16
E.2 Reasons for Public Offer or Admission to Trading	16
E.3 Fundraising Target	16
E.4 Minimum Subscription Goals	16
E.5 Maximum Subscription Goal	16
E.6 Oversubscription Acceptance	16
E.7 Oversubscription Allocation	16
E.8 Issue Price	16
E.9 Official Currency or Any Other Crypto-Assets Determining the Issue Price	16
E.10 Subscription Fee	16
E.11 Offer Price Determination Method	16
E.12 Total Number of Offered/Traded Crypto-Assets	16
E.13 Targeted Holders	17
E.14 Holder Restrictions	17
E.15 Reimbursement Notice	17
E.16 Refund Mechanism	17
E.17 Refund Timeline	17
E.18 Offer Phases	17
E.19 Early Purchase Discount	17
E.20 Time-Limited Offer	17
E.21 Subscription Period Beginning	17
E.22 Subscription Period End	17
E.23 Safeguarding Arrangements for Offered Funds/Crypto-Assets	17
E.24 Payment Methods for Crypto-Asset Purchase	17
E.25 Value Transfer Methods for Reimbursement	17
E.26 Right of Withdrawal	17
E.27 Transfer of Purchased Crypto-Assets	17

E.28 Transfer Time Schedule	17
E.29 Purchaser's Technical Requirements	17
E.30 Crypto-asset service provider (CASP) name	18
E.31 CASP identifier	18
E.32 Placement Form	18
E.33 Trading Platforms name	18
E.34 Trading Platforms Market Identifier Code (MIC)	18
E.35 Trading Platforms Access	18
E.36 Involved Costs	18
E.37 Offer Expenses	18
E.38 Conflicts of Interest	18
E.39 Applicable Law	18
E.40 Competent Court	18
F. PART F - INFORMATION ABOUT THE CRYPTO-ASSETS	19
F.1 Crypto-Asset Type	19
F.2 Crypto-Asset Functionality	19
F.3 Planned Application of Functionalities	19
F.4 Type of white paper	19
F.5 The type of submission	19
F.6 Crypto-Asset Characteristics	19
F.7 Commercial name or trading name	19
F.8 Website of the issuer	19
F.9 Starting date of offer to the public or admission to trading	19
F.10 Publication date	19
F.11 Any other services provided by the issuer	19
F.12 Language or languages of the white paper	19
F.13 Digital Token Identifier Code used to uniquely identify the crypto-asset or each of the several crypto assets to which the white paper relates, where available	19
F.14 Functionally Fungible Group Digital Token Identifier, where available	19
F.15 Voluntary data flag	19
F.16 Personal data flag	19
F.17 LEI eligibility	20
F.18 Home Member State	20
F.19 Host Member States	20
G. PART G - INFORMATION ON THE RIGHTS AND OBLIGATIONS ATTACHED TO THE CRYPTO-ASSETS	21
G.1 Purchaser Rights and Obligations	21
G.2 Exercise of Rights and Obligation	21
G.3 Conditions for Modifications of Rights and Obligations	21
G.4 Future Public Offers	21
G.5 Issuer Retained Crypto-Assets	21
G.6 Utility Token Classification	21
G.7 Key Features of Goods/Services of Utility Tokens	21
G.8 Utility Tokens Redemption	21
G.9 Non-Trading Request	21
G.10 Crypto-Assets Purchase or Sale Modalities	21
G.11 Crypto-Assets Transfer Restrictions	21

G.12 Supply Adjustment Protocols	21
G.13 Supply Adjustment Mechanisms	21
G.14 Token Value Protection Schemes	22
G.15 Token Value Protection Schemes Description	22
G.16 Compensation Schemes	22
G.17 Compensation Schemes Description	22
G.18 Applicable Law	22
G.19 Competent Court	22
H. PART H – INFORMATION ON THE UNDERLYING TECHNOLOGY	23
H.1 Distributed ledger technology	23
H.2 Protocols and Technical Standards	23
H.3 Technology Used	23
H.4 Consensus Mechanism	23
H.5 Incentive Mechanisms and Applicable Fees	23
H.6 Use of Distributed Ledger Technology	23
H.7 DLT Functionality Description	24
H.8 Audit	24
H.9 Audit Outcome	24
I. PART I – INFORMATION ON RISKS	25
I.1 Offer-Related Risks	25
I.2 Issuer-Related Risks	25
I.3 Crypto-Assets-Related Risks	25
I.4 Project Implementation-Related Risks	25
I.5 Technology-Related Risks	25
I.6 Mitigation Measures	25
J. PART J – INFORMATION ON THE SUSTAINABILITY INDICATORS IN RELATION TO ADVERSE IMPACT ON THE CLIMATE AND OTHER ENVIRONMENT-RELATED ADVERSE IMPACTS	26
J.1 Mandatory information on principal adverse impacts on the climate and other environment-related adverse impacts of the consensus mechanism	26
J.2 Supplementary information on principal adverse impacts on the climate and other environment-related adverse impacts of the consensus mechanism	27

01 DATE OF NOTIFICATION

2025-11-17

COMPLIANCE STATEMENTS

02 This crypto-asset white paper has not been approved by any competent authority in any Member State of the European Economic Area. The offeror of the crypto-asset is solely responsible for the content of this crypto-asset white paper.

Where relevant in accordance with Article 6(3), second subparagraph of Regulation (EU) 2023/1114, reference shall be made to 'person seeking admission to trading' or to 'operator of the trading platform' instead of 'offeror'.

03 This crypto-asset white paper complies with Title II of Regulation (EU) 2023/1114 and, to the best of the knowledge of the management body, the information presented in the crypto-asset white paper is fair, clear and not misleading and the crypto-asset white paper makes no omission likely to affect its import.

04 The crypto-asset referred to in this white paper may lose its value in part or in full, may not always be transferable and may not be liquid.

05 Not Applicable

06 The crypto-asset referred to in this white paper is not covered by the investor compensation schemes under Directive 97/9/EC of the European Parliament and of the Council. The crypto-asset referred to in this white paper is not covered by the deposit guarantee schemes under Directive 2014/49/EU of the European Parliament and of the Council.

SUMMARY

07 Warning

This summary should be read as an introduction to the crypto-asset white paper. The prospective holder should base any decision to purchase this crypto-asset on the content of the crypto-asset white paper as a whole and not on the summary alone. The offer to the public of this crypto-asset does not constitute an offer or solicitation to purchase financial instruments and any such offer or solicitation can be made only by means of a prospectus or other offer documents pursuant to the applicable national law.

This crypto-asset white paper does not constitute a prospectus as referred to in Regulation (EU) 2017/1129 of the European Parliament and of the Council (36) or any other offer document pursuant to Union or national law.

08 Characteristics of the crypto-asset

BIO is classified as a governance token rather than a security, giving holders rights to vote, influence funds, and access ecosystem advantages.

The initial supply is 3,320,000,000 BIO tokens.

Token lockups, vesting schedules, and gradual release over time are used to manage inflation and incentives.

09 Not applicable

10 Key information about the offer to the public or admission to trading

Here are the key information about the Bio Protocol (BIO):

<i>Total offer amount</i>	Not applicable
<i>Total number of tokens to be offered to the public</i>	Not Applicable
<i>Subscription period</i>	Not Applicable
<i>Minimum and maximum subscription amount</i>	Not Applicable
<i>Issue price</i>	Not Applicable
<i>Subscription fees (if any)</i>	Not Applicable
<i>Target holders of tokens</i>	Not Applicable
<i>Description of offer phases</i>	Not Applicable

<i>CASP responsible for placing the token (if any)</i>	Not Applicable
<i>Form of placement</i>	Not Applicable
<i>Admission to trading</i>	LCX AG, Herrengasse 6, 9490 Vaduz, Liechtenstein

A. PART A - INFORMATION ABOUT THE OFFEROR OR THE PERSON SEEKING ADMISSION TO TRADING

A.1 Name

LCX

A.2 Legal Form

AG

A.3 Registered Address

Herrengasse 6, 9490 Vaduz, Liechtenstein

A.4 Head Office

Herrengasse 6, 9490 Vaduz, Liechtenstein

A.5 Registration Date

24.04.2018

A.6 Legal Entity Identifier

529900SN07Z6RTX8R418

A.7 Another Identifier Required Pursuant to Applicable National Law

FL-0002.580.678-2

A.8 Contact Telephone Number

+423 235 40 15

A.9 E-mail Address

legal@lcx.com

A.10 Response Time (Days)

020

A.11 Parent Company

Not applicable

A.12 Members of the Management Body

Full Name	Business Address	Function
Monty C. M. Metzger	Herrengasse 6, 9490 Vaduz, Liechtenstein	President of the Board
Katarina Metzger	Herrengasse 6, 9490 Vaduz, Liechtenstein	Board Member
Anurag Verma	Herrengasse 6, 9490 Vaduz, Liechtenstein	Director of Technology

A.13 Business Activity

LCX provides various crypto-asset services under Liechtenstein's Token and Trusted Technology Service Provider Act ("Token- und Vertrauenswürdige Technologie-Dienstleister-Gesetz" in short "TvtG") also known as the Blockchain Act. These include custody and administration of crypto-assets, offering secure storage for clients' assets and private keys. LCX operates a trading platform, facilitating the matching of buy and sell orders for crypto-assets. It enables both crypto-to-fiat and crypto-to-crypto exchanges, ensuring compliance with AML and KYC regulations. LCX also supports token placements, marketing crypto-assets on behalf of offerors.

Under MiCA, LCX is classified as a Crypto-Asset Service Provider (CASP). LCX is not yet formally supervised under MiCA until the license is granted by the competent authority.

Under the TVTG framework, LCX provides:

- TT Depositary – Custody and safekeeping of crypto-assets.
- TT Trading Platform Operator – Operation of a regulated crypto-asset exchange.
- TT Exchange Service Provider – Crypto-to-fiat and crypto-to-crypto exchange.
- Token Issuer – Marketing and distribution of tokens.
- TT Transfer Service Provider – Crypto-asset transfers between ledger addresses.
- Token Generator & Tokenization Service Provider – Creation and issuance of tokens.
- Physical Validator – Enforcement of token-based rights on TT systems.
- TT Verification & Identity Service Provider – Legal capacity verification and identity registration.
- TT Price Service Provider – Providing aggregated crypto-asset price information.

A.14 Parent Company Business Activity

Not applicable

A.15 Newly Established

false

A.16 Financial Condition for the past three Years

LCX AG has a strong capital base, with CHF 1 million (approx. 1,126,000 USD) in share capital (Stammkapital) and a solid equity position (Eigenkapital) in 2023. The company has experienced fluctuations in financial performance over the past three years, reflecting the dynamic nature of the crypto market. While LCX AG recorded a loss in 2022, primarily due to a market downturn and a security breach, it successfully covered the impact through reserves. The company has remained financially stable, achieving revenues and profits in 2021, 2023 and 2024 while maintaining break-even operations.

In 2023 and 2024, LCX AG strengthened its operational efficiency, expanded its business activities, and upheld a stable financial position. Looking ahead to 2025, the company anticipates positive financial development, supported by market uptrends, an inflow of customer funds, and strong business performance. Increased adoption of digital assets and service expansion are expected to drive higher revenues and profitability, further reinforcing LCX AG's financial position.

A.17 Financial Condition Since Registration

LCX AG has been financially stable since its registration, supported by CHF 1 million in share capital (Stammkapital) and continuous business growth. Since its inception, the company has expanded its operations, secured multiple regulatory registrations, and established itself as a key player in the crypto and blockchain industry.

While market conditions have fluctuated, LCX AG has maintained strong revenues and break-even operations. The company has consistently reinvested in its platform, technology, and regulatory compliance, ensuring long-term sustainability. The LCX Token has been a fundamental part of the ecosystem, with a market capitalization of approximately \$200 million USD and an all-time high exceeding \$500 million USD in 2022. Looking ahead, LCX AG anticipates continued financial growth, driven by market uptrends, increased adoption of digital assets, and expanding business activities.

B. PART B - INFORMATION ABOUT THE ISSUER, IF DIFFERENT FROM THE OFFEROR OR PERSON SEEKING ADMISSION TO TRADING

B.1 Issuer different from offeror or person seeking admission to trading

True

B.2 Name

Bio.xyz Association

B.3 Legal Form

Not Available

B.4 Registered Address

Not Available

B.5 Head Office

Not Available

B.6 Registration Date

Not Available

B.7 Legal Entity Identifier

Not Available

B.8 Another Identifier Required Pursuant to Applicable National Law

Not Available

B.9 Parent Company

Not Available

B.10 Members of the Management Body

Not Available

B.11 Business Activity

Not Available

B.12 Parent Company Business Activity

Not Available

C. PART C - INFORMATION ABOUT THE OPERATOR OF THE TRADING PLATFORM IN CASES WHERE IT DRAWS UP THE CRYPTO-ASSET WHITE PAPER AND INFORMATION ABOUT OTHER PERSONS DRAWING THE CRYPTO-ASSET WHITE PAPER PURSUANT TO ARTICLE 6(1), SECOND SUBPARAGRAPH, OF REGULATION (EU) 2023/1114

C.1 Name

LCX AG

C.2 Legal Form

AG

C.3 Registered Address

Herrengasse 6, 9490 Vaduz, Liechtenstein

C.4 Head Office

Herrengasse 6, 9490 Vaduz, Liechtenstein

C.5 Registration Date

24.04.2018

C.6 Legal Entity Identifier

529900SN07Z6RTX8R418

C.7 Another Identifier Required Pursuant to Applicable National Law

FL-0002.580.678-2

C.8 Parent Company

Not Applicable

C.9 Reason for Crypto-Asset White Paper Preparation

LCX is preparing this MiCA-compliant whitepaper for BIO to enhance transparency, regulatory clarity, and investor confidence. While BIO has classification as "Other Crypto Asset," LCX is providing this document to support its role as a Crypto-Asset Service Provider (CASP) and ensure compliance with MiCA regulations in facilitating BIO trading on its platform.

C.10 Members of the Management Body

Full Name	Business Address	Function
Monty C. M. Metzger	Herrengasse 6, 9490 Vaduz, Liechtenstein	President of the Board
Katarina Metzger	Herrengasse 6, 9490 Vaduz, Liechtenstein	Board Member
Anurag Verma	Herrengasse 6, 9490 Vaduz, Liechtenstein	Director of Technology

C.11 Operator Business Activity

LCX provides various crypto-asset services under Liechtenstein's Token and Trusted Technology Service Provider Act ("Token- und Vertrauenswürdige Technologie-Dienstleister-Gesetz" in short "TvtG") also known as the Blockchain Act. These include custody and administration of crypto-assets, offering secure storage for clients' assets and private keys. LCX operates a trading platform, facilitating the matching of buy and sell orders for crypto-assets. It enables both crypto-to-fiat and crypto-to-crypto exchanges, ensuring compliance with AML and KYC regulations. LCX also supports token placements, marketing crypto-assets on behalf of offerors.

Under MiCA, LCX is classified as a Crypto-Asset Service Provider (CASP).

Under the TVTG framework, LCX provides:

- TT Depository – Custody and safekeeping of crypto-assets.
- TT Trading Platform Operator – Operation of a regulated crypto-asset exchange.
- TT Exchange Service Provider – Crypto-to-fiat and crypto-to-crypto exchange.
- Token Issuer – Marketing and distribution of tokens.
- TT Transfer Service Provider – Crypto-asset transfers between ledger addresses.
- Token Generator & Tokenization Service Provider – Creation and issuance of tokens.
- Physical Validator – Enforcement of token-based rights on TT systems.
- TT Verification & Identity Service Provider – Legal capacity verification and identity registration.
- TT Price Service Provider – Providing aggregated crypto-asset price information.

C.12 Parent Company Business Activity

Not Applicable

C.13 Other persons drawing up the white paper under Article 6 (1) second subparagraph MiCA

Not Applicable

C.14 Reason for drawing up the white paper under Article 6 (1) second subparagraph MiCA

Not Applicable

D. PART D - INFORMATION ABOUT THE CRYPTO-ASSET PROJECT

D.1 Crypto-Asset Project Name

Bio Protocol

D.2 Crypto-Assets Name

BIO

D.3 Abbreviation

BIO

D.4 Crypto-Asset Project Description

BIO Protocol is a decentralized science (DeSci) infrastructure platform designed to coordinate, fund, and govern biotech and scientific research through a blockchain-native system. It connects researchers, funders, and communities via a set of smart contracts and decentralized autonomous organizations (BioDAOs), enabling transparent allocation of capital, tokenized ownership of intellectual property (IP), and community-driven prioritization of research projects. At its core, the BIO token serves as a governance asset, allowing holders to vote on funding decisions, access early-stage biotech opportunities, and influence the direction of scientific innovation. BIO aims to create a more open, incentive-aligned, and democratized ecosystem for life sciences R&D by merging Web3 technologies with biotech funding and IP frameworks.

D.5 Details of all persons involved in the implementation of the crypto-asset project

These people/entities collaborate to maintain and improve the BIO(Bio Protocol) token ecosystem:

Full Name	Business Address	Function
Paul Kohlhaas:	<i>Not Applicable</i>	<i>Co-founder and CEO of BIO</i>
Clemens Ortlepp	<i>Not Applicable</i>	<i>CPO</i>
Bio.xyz Association	<i>Not Available</i>	<i>Protocol treasury and governance</i>

D.6 Utility Token Classification

False

D.7 Key Features of Goods/Services for Utility Token Projects

Not Applicable

D.8 Plans for the Token

The token launch (January 2025) already deployed the core smart contracts and BioDAO Launchpad.

The roadmap includes scaling the number of BioDAOs, expanding IP tokenization infrastructure, integrating AI research agents, and expanding cross-chain operations.

Governance proposals can adjust issuance, ecosystem incentives, or new protocol extensions under community control.

D.9 Resource Allocation

According to its whitepaper, of the token allocations: 5 % is allotted to the Molecule Ecosystem Fund, and 25 % for Ecosystem Initiatives, with the remainder distributed among community, investors, contributors, advisors etc.

Also, BIO raised ~USD 30 M in 2024 plus ~USD 64 M in a public sale, which contributes to its treasury.

Lockups and vesting schedules are used to ensure long-term alignment.

D.10 Planned Use of Collected Funds or Crypto-Assets

Funds collected are intended to support research infrastructure, development of IP tokenization frameworks, AI systems, and acceleration of BioDAOs via grants and development subsidies.

The portion allocated to Ecosystem Initiatives will be distributed by governance proposals to support new biotech projects in the ecosystem.

The Molecule Ecosystem Fund is designated for research, IP tokenization, and AI infrastructure development.

E. PART E - INFORMATION ABOUT THE OFFER TO THE PUBLIC OF CRYPTO-ASSETS OR THEIR ADMISSION TO TRADING

E.1 Public Offering or Admission to Trading

ATTR

E.2 Reasons for Public Offer or Admission to Trading

LCX is filing a MiCA-compliant whitepaper for BIO to enhance transparency, regulatory clarity, and investor confidence. While BIO is classified as “Other Crypto-Assets” under MiCA, this initiative supports compliance readiness and aligns with MiCA’s high disclosure standards. By doing so, LCX strengthens its position as a regulated exchange, ensuring a trustworthy and transparent trading environment for BIO within the EU’s evolving regulatory framework. Additionally, this filing facilitates market access and institutional adoption by removing uncertainty for institutional investors and regulated entities seeking to engage with BIO in a compliant manner. It further supports the broader market adoption and integration of BIO into the regulated financial ecosystem, reinforcing LCX’s role in shaping compliant and transparent crypto markets.

E.3 Fundraising Target

Not applicable

E.4 Minimum Subscription Goals

Not applicable

E.5 Maximum Subscription Goal

Not applicable

E.6 Oversubscription Acceptance

Not applicable

E.7 Oversubscription Allocation

Not applicable

E.8 Issue Price

Not applicable

E.9 Official Currency or Any Other Crypto-Assets Determining the Issue Price

Not applicable

E.10 Subscription Fee

Not applicable

E.11 Offer Price Determination Method

Not applicable

E.12 Total Number of Offered/Traded Crypto-Assets

BIO Protocol has a fixed supply of 3,320,000,000 BIO tokens.

E.13 Targeted Holders

ALL

E.14 Holder Restrictions

Not applicable

E.15 Reimbursement Notice

Not applicable

E.16	Refund Mechanism	
	Not applicable	
E.17	Refund Timeline	
	Not applicable	
E.18	Offer Phases	
	Not applicable	
E.19	Early Purchase Discount	
	Not applicable	
E.20	Time-Limited Offer	
	Not applicable	
E.21	Subscription Period Beginning	
	Not applicable	
E.22	Subscription Period End	
	Not applicable	
E.23	Safeguarding Arrangements for Offered Funds/Crypto-Assets	
	Not applicable	
E.24	Payment Methods for Crypto-Asset Purchase	
	Not applicable	
E.25	Value Transfer Methods for Reimbursement	
	Not applicable	
E.26	Right of Withdrawal	
	Not applicable	
E.27	Transfer of Purchased Crypto-Assets	
	Not applicable	
E.28	Transfer Time Schedule	
	Not applicable	
E.29	Purchaser's Technical Requirements	
	Not applicable	
E.30	Crypto-asset service provider (CASP) name	
	Not applicable	
E.31	CASP identifier	
	Not applicable	
E.32	Placement Form	
	NTAV	
E.33	Trading Platforms name	
	LCX AG	
E.34	Trading Platforms Market Identifier Code (MIC)	
	LCXE	

E.35 Trading Platforms Access

BIO is widely traded on multiple regulated and unregulated trading platforms globally. BIO is not restricted to a single exchange and can be accessed by retail and institutional investors worldwide.

LCX Exchange also provides access to BIO trading with the BIO/EUR pair. Investors can access BIO through LCX.com, the official LCX exchange, as well as other supported cryptocurrency trading platforms. To trade BIO, users must register, complete KYC (Know Your Customer) verification, and comply with platform-specific requirements.

E.36 Involved Costs

Not applicable

E.37 Offer Expenses

Not applicable

E.38 Conflicts of Interest

Not Applicable

E.39 Applicable Law

For admission to trading of BIO on LCX, the applicable law is Liechtenstein law, applied in accordance with MiCA and EU regulations. For decentralized, on-chain use of BIO outside LCX, applicable law depends on the user's jurisdiction.

E.40 Competent Court

Any disputes related to services provided by LCX fall under the jurisdiction of the Courts of Liechtenstein. For independent on-chain activities with BIO, no centralized legal recourse exists.

F. PART F - INFORMATION ABOUT THE CRYPTO-ASSETS

F.1 **Crypto-Asset Type**

Other Crypto-Asset

F.2 **Crypto-Asset Functionality**

BIO functions as a governance token: holders stake or lock BIO to obtain voting power (veBIO) to decide which BioDAOs to support, how the treasury is spent, and protocol-level upgrades.

It also grants access to early rounds of BioDAO funding, whitelist benefits, curation of projects, and incentive rewards for contributions to research or protocol services.

Additionally, BIO may be used as liquidity backing, interoperability with IP tokens, or staking for yield/incentives.

F.3 **Planned Application of Functionalities**

The plan is for BIO to underlie a DeSci (decentralized science) ecosystem: BioDAOs will propose biotech or scientific research projects, and token holders will vote to fund them.

BIO will enable transparent funding flows, tokenized ownership of IP, and community-driven prioritization of scientific initiatives.

In future, AI agents (like “Aubrai”) may coordinate research tasks or suggest proposals, integrating with the BIO governance framework.

F.4 **Type of white paper**

OTHR

F.5 **The type of submission**

NEWT

F.6 **Crypto-Asset Characteristics**

BIO is classified as a governance token rather than a security, giving holders rights to vote, influence funds, and access ecosystem advantages.

The initial supply is 3,320,000,000 BIO tokens.

Token lockups, vesting schedules, and gradual release over time are used to manage inflation and incentives.

F.7 **Commercial name or trading name**

BIO

F.8 **Website of the issuer**

<https://www.bio.xyz/>

F.9 **Starting date of offer to the public or admission to trading**

2025-12-17

F.10 **Publication date**

2025-12-17

F.11 **Any other services provided by the issuer**

Not applicable

F.12 **Language or languages of the white paper**

English

F.13 Digital Token Identifier Code used to uniquely identify the crypto-asset or each of the several crypto assets to which the white paper relates, where available
TBR0XDRN8

F.14 Functionally Fungible Group Digital Token Identifier, where available
Not Available

F.15 Voluntary data flag
true

F.16 Personal data flag
false

F.17 LEI eligibility
false

F.18 Home Member State
Liechtenstein

F.19 Host Member States
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.

G. PART G - INFORMATION ON THE RIGHTS AND OBLIGATIONS ATTACHED TO THE CRYPTO-ASSETS

G.1 Purchaser Rights and Obligations

Rights:

Access to goods/services over Website/Platform.

Participation in events and features requiring BIO.

Use of tokens for staking or governance voting (non-binding)

Obligations:

Use BIO only for its intended purposes.

Acknowledge that holding BIO does not grant ownership, dividends, or profit rights

G.2 Exercise of Rights and Obligation

Token rights are exercised via the Penguin Platform interface:

In-Platform Use: BIO can be redeemed directly for services, items, or access.

Staking/Voting: Users can connect eligible wallets to participate in staking or polls (if any).

Conditions: Rights are contingent upon availability of services and compliance with platform rules.

G.3 Conditions for Modifications of Rights and Obligations

The issuer reserves the right to modify token rights or obligations under the following conditions:

Regulatory Compliance: Changes required by law or MiCA regulations

Platform Updates: Adjustments due to technical or functional upgrades

User Notification: Material changes will be communicated in advance via official channels

User Agreement: Continued use of the platform or tokens implies acceptance of updated terms

G.4 Future Public Offers

Not applicable

G.5 Issuer Retained Crypto-Assets

Not applicable

G.6 Utility Token Classification

False

G.7 Key Features of Goods/Services of Utility Tokens

Not Applicable

G.8 Utility Tokens Redemption

Not applicable

G.9 Non-Trading Request

True

G.10 Crypto-Assets Purchase or Sale Modalities

Not applicable

G.11 Crypto-Assets Transfer Restrictions

Not applicable

G.12 Supply Adjustment Protocols

False

G.13 Supply Adjustment Mechanisms

Not Applicable

G.14 Token Value Protection Schemes

False

G.15 Token Value Protection Schemes Description

Not Applicable

G.16 Compensation Schemes

False

G.17 Compensation Schemes Description

Not Applicable

G.18 Applicable Law

For admission to trading of BIO on LCX, the applicable law is Liechtenstein law, applied in accordance with MiCA and EU regulations. For decentralized, on-chain use of BIO outside LCX, applicable law depends on the user's jurisdiction.

G.19 Competent Court

Any disputes related to services provided by LCX fall under the jurisdiction of the Courts of Liechtenstein. For independent on-chain activities with BIO, no centralized legal recourse exists.

H. PART H – INFORMATION ON THE UNDERLYING TECHNOLOGY

H.1 Distributed ledger technology

BIO Protocol is built on public blockchains as the foundational distributed ledger infrastructure. The protocol leverages smart contracts deployed on these chains to ensure transparency, immutability, and decentralization of transactions, governance votes, and token operations.

H.2 Protocols and Technical Standards

BIO adheres to standard token and contract protocols for interoperability (for example, ERC-20 (or equivalent) on Ethereum) to ensure compatibility with wallets, exchanges, and tooling. Its governance and staking mechanisms also conform to “vote-escrow” token models (veBIO) for locking tokens to gain voting power, a model used in DeFi governance protocols.

H.3 Technology Used

The core technology stack includes smart contracts on Ethereum for token issuance, staking, governance, and decentralized autonomous organizations (BioDAOs).

It also uses mechanisms for IP tokenization (minting intellectual property tokens) to represent fractional ownership of biotech discoveries.

Off-chain oracles, DAO governance modules, and possibly AI agents for research coordination (e.g. “Aubrai”) complement the system.

H.4 Consensus Mechanism

BIO uses Ethereum’s proof of stakes as a consensus mechanism.

H.5 Incentive Mechanisms and Applicable Fees

BIO uses Ethereum’s existing incentive mechanisms and fee structure.

H.6 Use of Distributed Ledger Technology

True

H.7 DLT Functionality Description

The underlying DLT ensures:

Transparency: All token transfers and contract interactions are publicly verifiable

Security: Immutable ledger protects against unauthorized changes

Automation: Smart contracts enforce token logic without manual intervention

Interoperability: Compatible with major DeFi tools, exchanges.

H.8 Audit

True

H.9 Audit Outcome

The BIO token smart contracts have been audited by an independent third-party security firm. Key outcomes:

No critical vulnerabilities found

Medium and low-risk findings addressed prior to deployment

Audit reports can be accessed through this link: <https://www.cyberscope.io/audits/coin-bio>.

I. PART I – INFORMATION ON RISKS

I.1 Offer-Related Risks

Market Volatility: The value of BIO may fluctuate significantly after launch.

Insufficient Demand: The offering may not attract the expected user base or funding.

Limited Liquidity: There is no guarantee of active secondary markets for trading BIO.

I.2 Issuer-Related Risks

Operational Risk: The issuing entity may face financial, legal, or management issues.

Regulatory Risk: Future regulatory changes could impact the issuer's ability to operate.

Dependence on Key Personnel: Loss of core team members may affect the project's progress.

I.3 Crypto-Assets-Related Risks

Price Volatility: Crypto-assets in general are subject to high price fluctuations.

Cybersecurity Threats: Wallets, exchanges, or smart contracts may be vulnerable to attacks.

Lack of Legal Recourse: Users may have limited remedies in the event of token loss or theft.

I.4 Project Implementation-Related Risks

Delays: Project features or milestones may be postponed or fail to launch.

Resource Constraints: Funding shortfalls or technical challenges may affect delivery.

Integration Failure: Planned partnerships or features may not materialize as expected.

I.5 Technology-Related Risks

Smart Contract Bugs: Undiscovered flaws in deployed contracts could cause failures.

Blockchain Dependencies: Reliance on the underlying blockchain (e.g., Solana or other) may introduce external risks like congestion or forks.

System Downtime: Platform outages or infrastructure failure could disrupt service.

I.6 Mitigation Measures

Audits: Smart contracts are subject to independent security audits.

Vesting and Reserves: Controlled token releases reduce the risk of market shocks.

Regulatory Alignment: The project is designed to comply with MiCA and EU laws.

Transparency: Regular updates and on-chain data provide user visibility and trust.

Contingency Planning: A reserve fund and legal structure are in place to handle operational risks.

J. PART J – INFORMATION ON THE SUSTAINABILITY INDICATORS IN RELATION TO ADVERSE IMPACT ON THE CLIMATE AND OTHER ENVIRONMENT-RELATED ADVERSE IMPACTS

Adverse impacts on climate and other environment-related adverse impacts.

J.1 Information on principal adverse impacts on the climate and other environment-related adverse impacts of the consensus mechanism

The BIO token operates on a user-friendly, scalable blockchain infrastructure, optimized for accessibility and low-cost transactions. The platform's low environmental impact and commitment to sustainable operations align with MiCA's standards for distributed ledger technologies. The network's annual energy consumption is 637.53087 kWh/a.

General information	
S.1 Name <i>Name reported in field A.1</i>	LCX
S.2 Relevant legal entity identifier <i>Identifier referred to in field A.2</i>	529900SN07Z6RTX8R418
S.3 Name of the crypto-asset <i>Name of the crypto-asset, as reported in field D.2</i>	Bio Protocol
S.4 Consensus Mechanism <i>The consensus mechanism, as reported in field H.4</i>	Ethereum's Proof of Stakes
S.5 Incentive Mechanisms and Applicable Fees <i>Incentive mechanisms to secure transactions and any fees applicable, as reported in field H.5</i>	Ethereum's existing incentive mechanisms and fee structure.
S.6 Beginning of the period to which the disclosure relates	2024-05-18
S.7 End of the period to which the disclosure relates	2024-05-18
Mandatory key indicator on energy consumption	
S.8 Energy consumption <i>Total amount of energy used for the validation of transactions and the maintenance of the integrity of the distributed ledger of transactions, expressed per calendar year</i>	637.53087 kWh per year
Sources and methodologies	
S.9 Energy consumption sources and Methodologies <i>Sources and methodologies used in relation to the information reported in field S.8</i>	The energy consumption of the BIO token is calculated using a bottom-up approach, focusing on node activity. Public data, open-source tools, and certified lab tests inform estimates. Network-level energy use is attributed to the token based on its gas usage,

	using FFG DTI data to identify asset implementations.
--	---

J.2 Supplementary information on principal adverse impacts on the climate and other environment-related adverse impacts of the consensus mechanism

Not Applicable